甲磺酸伊马替尼干扰素-α单用或联用治疗CML临床对比研究(已修改).docVIP

甲磺酸伊马替尼、干扰素-α单用或联用治疗CML临床对比研究 【摘要】目的: 探讨甲磺酸伊马替尼、干扰素-α单用或联用治疗CML临床效果差异。方法：选取我院20年月-201年月收治CML患者180例，采用随机数字表法分为三组，即A组、B组及C组，每组各0例，分别采用甲磺酸伊马替尼、干扰素-α单用，比较三组患者等。结果：C组患者显著于A、B组，差异有统计学意义（p0.05）；C组患者均显著优于A、B组，差异有统计学意义（p0.05）；组患者显著优于B组，差异有统计学意义（p0.05）；C组患者显著于A、B组，差异有统计学意义（p0.05）；C组患者显著于A、B组，差异有统计学意义（p0.05）；C组患者显著于A、B组，差异有统计学意义（p0.05）。结论：甲磺酸伊马替尼干扰素-α联用治疗CML可有效，，，疗效优于甲磺酸伊马替尼、干扰素-α单用。 【关键词】甲磺酸伊马替尼干扰素-αCML；疗效Clinical comparative study of imatinib mesylate, interferon-α used alone or in combination treatment on patients with CML Abstract：Objective To investigate clinical effects differences of?imatinib mesylatenterferon-α used alone or in combination treatment on patients with CML. Methods 180 patients with CML were chosen in our hospital in the period from January 2009 to December 2012 and randomly divided into 3 groups including A group (60 patients) with imatinib mesylate used alone, B group (60 patients) with interferon-α used alone and C group (60 patients) with imatinib mesylate combined withinterferon-α; and the hematologic efficacy, remission rate of cytogenetics and molecular biology, disappear time of symptoms and signs, blast rate of CML, no disease-free survival rate and overall survival rate with follow-up of 3 groups were compared. Results The hematologic efficacy of C group was significant better than A group and B group（p0.05）. The remission rate of cytogenetics and molecular biology of C group after treatment was significant better than A group and B group（p0.05）. The remission rate of cytogenetics and molecular biology of A group after treatment was significant better than B group（p0.05）. The disappear time of symptoms and signs of group after treatment was significant better than A group and B group（p0.05）. The blast rate of CML of C group after treatment was significant better than A group and B group（p0.05）. The no disease-free survival rate and overall survival rate with follow-up of group after treatment was significant better than A group and B group（